Esta estadística muestra la evolución anual del número de muertes por síndrome mielodisplásico en Cataluña de 2005 a 2017. En el año 2017, se registraron un total de 210 muertes debido a este tipo de
Supplementary Table 1. Inflation adjustment based on calendar year averages.Supplementary Table 2. Nominal cost outcomes up to 3-year follow-up (LS-means and p-value were adjusted for all baseline com
The nucleotide analogue azacitidine (AZA) interferes with RNA and DNA metabolism and is currently the best treatment option for a subset of patients with high-risk myelodysplastic syndromes. However,
Aberrant innate immune signaling in myelodysplastic syndrome (MDS) hematopoietic stem/progenitor cells (HSPCs) has been implicated as a driver of the development of MDS. We herein demonstrated that an